Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYBB | P04839 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15732211 | 0.88 | OPRM1 (0.39) | OPRK1OPRM1OPRD1CYP2D6LMNA | |
| SCHEMBL15214352 | 0.86 | OPRK1 (0.53) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL16747749 | 0.86 | OPRK1 (0.53) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL14996104 | 0.86 | OPRK1 (0.53) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL15732181 | 0.82 | — | — | |
| SCHEMBL15732231 | 0.82 | OPRK1 (0.40) | OPRK1OPRM1OPRD1CYP2D6CHRNA7 | |
| SCHEMBL15732206 | 0.80 | OPRM1 (0.56) | OPRK1OPRM1OPRD1CYP2D6LMNA | |
| SCHEMBL16743664 | 0.80 | OPRM1 (0.56) | OPRK1OPRM1OPRD1CYP2D6LMNA | |
| SCHEMBL16705041 | 0.79 | OPRM1 (0.54) | OPRK1OPRM1OPRD1 | |
| SCHEMBL15337209 | 0.79 | OPRM1 (0.54) | OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853232-B2 | Peripheral opioid receptor antagonists and uses thereof | WYETH LLC (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140142132-A1 | PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF | WYETH, LLC (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142132-A1 | PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF | OPRM1, OPRL1, OPRK1 | OPRK1 3/4885OPRM1 1/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.